| Literature DB >> 33297552 |
Flora Kuehne1, Linda Sanftenberg1, Tobias Dreischulte1, Jochen Gensichen1.
Abstract
Insufficient vaccination rates against pneumococcal disease are a major problem in primary health care, especially in adult patients. Shared decision-making (SDM) may address major barriers to vaccination. The objective of this review was to assess the impact of SDM on pneumococcal vaccination rates in adult patients. We conducted a systematic literature search in MEDLINE, EMBASE, CENTRAL, PsycINFO, and ERIC. RCTs and cluster RCTs were included, if they aimed to enhance pneumococcal vaccination rates in adult patients and comprised a personal interaction between health care provider (HCP) and patient. Three further aspects of the SDM process (patient activation, bi-directional exchange of information and bi-directional deliberation) were assessed. A meta-analysis was conducted for the effects of interventions on vaccination rates. We identified eight studies meeting the inclusion criteria. The pooled effect size was OR (95% CI): 2.26 (1.60-3.18) comparing intervention and control groups. Our findings demonstrate the efficacy of interventions that enable a SDM process to enhance pneumococcal vaccination rates; although, the quality of evidence was low. In exploratory subgroup analyses, we concluded that an impersonal patient activation and an exchange of information facilitated by nurses are sufficient to increase vaccination rates against pneumococcal disease in adult patients. However, the deliberation of options between physicians and patients seemed to be more effective than deliberation of options between nurses and patients.Entities:
Keywords: pneumococcal; shared decision making; vaccination
Mesh:
Year: 2020 PMID: 33297552 PMCID: PMC7729624 DOI: 10.3390/ijerph17239146
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flowchart.
Characteristics of included studies.
| Study | Country | Patients/Age | Intervention | Vaccination Rate (IG) | Vaccination Rate (CG) | Effect Size/ | Follow up | ||
|---|---|---|---|---|---|---|---|---|---|
| Chan 2015 * (44) | Hong Kong | 65+ with chronic | Telephone outreach and face-to-face session | 57.2% | 48.1% | 1251 | 1266 | ARR (95% CI): 1.20 (1.06–1.37) | 3 months |
| Coenen 2017 * (37) | Belgium | Inflammatory | Face-to-face session | 62% | 23% | 86 (PP) | 107 (PP) | 8 months | |
| Dapp 2011 * (38) | Germany | 60+ | Computer generated feedback for patient and HCP, | 47% | 23.8% | 568 | 1342 | OR (95% CI): 2.8 | 1 year |
| Jacobson | USA | 65+ or chronic | Discussion empowering educational material | 19.9% | 3.8% | 221 | 212 | RR (95% CI): 5.28 | 1 day |
| Klassing 2018 (40) | USA | 18+ with | Telephone outreach | 59.7% | 55.7% | 77 (PP) | 70 (PP) | 5 months | |
| Parker | USA | 18+ lymphoma | New face-to-face consultation and communication skills | 14% | 14% | 117 | 81 | logistic HLM: OR | 12 months |
| Stuck 2015 | Switzerland | 65+ | Computer generated feedback for patient and HCP, | 31.3% | 20.2% | 827 | 1320 | OR (95% CI): 1.90 | 2 years |
| Zwar 2012 | Australia | 40–80 years with | Face-to-face session (home visit) | 72.7% | 61.7% | 161 | 169 | OR 1.64 (0.93–2.89), | 12 months |
* p < 0.05; ITT: intention-to-treat; PP: per-protocol; IG: intervention group; CG: control group.
Figure 2Forest plot (meta-analysis) of effects on vaccination rates.
Subgroup analyses (meta-analysis).
| Subgroup | Number of Studies | OR (95% CI) | I2 |
|---|---|---|---|
| Activation | |||
| impersonal | 3 [ | 2.79 (1.73–4.50) * | 88% |
| by nurse | 2 [ | 1.49 (1.15–1.93) * | 0% |
| by physician | 2 [ | 2.50 (0.40–15.52) | 92% |
| Information | |||
| by nurse | 5 [ | 2.32 (1.57–3.43) * | 88% |
| by physician | 2 [ | 2.48 (0.39–15.95) | 90% |
| Deliberation | |||
| by nurse | 3 [ | 2.42 (0.99–5.89) | 91% |
| by physician | 4 [ | 2.38 (1.50–3.77) * | 85% |
Activation: patient activation; Information: bi-directional exchange of information; Deliberation: bi-directional deliberation of options; * p < 0.05; I2: measurement of heterogeneity.
Figure 3Risk of Bias assessment; (a) Risk of Bias summary; (b) Risk of Bias graph.